Cargando…

IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer

Relapse to anti-HER2 monoclonal antibody (mAb) therapies, such as trastuzumab in HER2(+) breast cancer (BC), is associated with residual disease progression due to resistance to therapy. Here, we identify interferon-γ inducible protein 16 (IFI16)-dependent STING signaling as a significant determinan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ong, Li-Teng, Lee, Wee Chyan, Ma, Shijun, Oguz, Gokce, Niu, Zhitong, Bao, Yi, Yusuf, Mubaraka, Lee, Puay Leng, Goh, Jian Yuan, Wang, Panpan, Yong, Kylie Su Mei, Chen, Qingfeng, Wang, Wenyu, Ramasamy, Adaikalavan, Hoon, Dave S. B., Ditzel, Henrik J., Tan, Ern Yu, Lee, Soo Chin, Yu, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2022
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351446/ https://www.ncbi.nlm.nih.gov/pubmed/35878022 http://dx.doi.org/10.1073/pnas.2201376119

Ejemplares similares

EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
por: Bao, Yi, et al.
Publicado: (2020)

Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy
por: Ma, Shijun, et al.
Publicado: (2022)

KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer
por: Wang, Wenyu, et al.
Publicado: (2018)

Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer
por: Wang, Wenyu, et al.
Publicado: (2021)

IFI16 and cGAS cooperate in the activation of STING during DNA sensing in human keratinocytes
por: Almine, Jessica F., et al.
Publicado: (2017)

Overexpression of HER2/HER3 and clinical feature of ovarian cancer
por: Chung, Ye Won, et al.
Publicado: (2019)

Evaluating Low HER2 Status in Invasive Breast Carcinoma via HER2 Immunohistochemistry, with HER2 FISH Correlation: A Cohort of 112 Patients
por: Ardor, Gokce Deniz, et al.
Publicado: (2023)

Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers
por: Choi, Byoungsan, et al.
Publicado: (2020)

STING-mediated degradation of IFI16 negatively regulates apoptosis by inhibiting p53 phosphorylation at serine 392
por: Li, Dapei, et al.
Publicado: (2021)

A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway
por: Wu, Xiaohan, et al.
Publicado: (2023)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Robust Guidelines for the Management of HR+ Her2− EBC: Crucial Value of CanAssist Breast
por: Vaid, Ashok, et al.
Publicado: (2022)

Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody)
por: Kim, Hyun Jung, et al.
Publicado: (2020)

A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells
por: Kim, Sangmin, et al.
Publicado: (2012)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes
por: Kayikcioglu, Erkan, et al.
Publicado: (2023)

SAMHD1 silencing cooperates with radiotherapy to enhance anti-tumor immunity through IFI16-STING pathway in lung adenocarcinoma
por: Li, Yangyi, et al.
Publicado: (2022)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas
por: Wang, Xin-Yu, et al.
Publicado: (2019)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

Serial Serum HER2 Measurements for the Detection of Breast Cancer Recurrence in HER2-Positive Patients
por: Ha, June-Hyung, et al.
Publicado: (2014)

The Crucial Roles and Research Advances of cGAS-STING Pathway in Cutaneous Disorders
por: Huang, Cong, et al.
Publicado: (2023)

Increased Ifi202b/IFI16 expression stimulates adipogenesis in mice and humans
por: Stadion, Mandy, et al.
Publicado: (2018)

“Everything for Her!”
por: Andrijević Matovac, Vesna
Publicado: (2011)

In her family /
por: Metheny, Pat
Publicado: (1987)

ADVICE TO THE EXPECTANT MOTHER ON THE CARE OF HER HEALTH AND THAT OF HER CHILD
Publicado: (1947)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

Advice to the Expectant Mother on the Care of Her Health and That of Her Child
Publicado: (1947)

Advice to the Expectant Mother on the Care of Her Health and That of Her Child
Publicado: (1943)

Advice to the Expectant Mother on the Care of Her Health and That of Her Child
Publicado: (1941)

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans
por: Vicencio, J. M., et al.
Publicado: (2022)

Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention
por: Nocera, Nadia F., et al.
Publicado: (2016)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Telomeres get SIRT-ified
por: Short, Ben
Publicado: (2010)

Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
por: Kang, Byeongju, et al.
Publicado: (2023)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_07oe3ub9objd4qspda0ras9hh2